Image source: Celldex Therapeutics
Clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) stock took a pounding recently, and the market hasn’t let up since. Its first drug, Rintega, performed in line with previous results in earlier trials with brain cancer patients, but during its first controlled trial, the group receiving the standard of care shocked everyone by outperforming historical averages.